Logo image of SYBX

SYNLOGIC INC (SYBX) Stock Fundamental Analysis

NASDAQ:SYBX - Nasdaq - US87166L2097 - Common Stock - Currency: USD

1.36  -0.05 (-3.55%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to SYBX. SYBX was compared to 571 industry peers in the Biotechnology industry. While SYBX seems to be doing ok healthwise, there are quite some concerns on its profitability. SYBX is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year SYBX has reported negative net income.
SYBX had a negative operating cash flow in the past year.
In the past 5 years SYBX always reported negative net income.
SYBX had a negative operating cash flow in each of the past 5 years.
SYBX Yearly Net Income VS EBIT VS OCF VS FCFSYBX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M

1.2 Ratios

SYBX has a Return On Assets of -331.21%. This is amonst the worse of the industry: SYBX underperforms 95.72% of its industry peers.
SYBX has a worse Return On Equity (-524.44%) than 80.93% of its industry peers.
Industry RankSector Rank
ROA -331.21%
ROE -524.44%
ROIC N/A
ROA(3y)-56.71%
ROA(5y)-47.7%
ROE(3y)-85.16%
ROE(5y)-67.93%
ROIC(3y)N/A
ROIC(5y)N/A
SYBX Yearly ROA, ROE, ROICSYBX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SYBX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SYBX Yearly Profit, Operating, Gross MarginsSYBX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -2K -4K -6K -8K -10K

More info and screens

5

2. Health

2.1 Basic Checks

SYBX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SYBX has more shares outstanding
SYBX has more shares outstanding than it did 5 years ago.
SYBX has a worse debt/assets ratio than last year.
SYBX Yearly Shares OutstandingSYBX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M
SYBX Yearly Total Debt VS Total AssetsSYBX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -33.26, we must say that SYBX is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of SYBX (-33.26) is worse than 92.16% of its industry peers.
SYBX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -33.26
ROIC/WACCN/A
WACC9.51%
SYBX Yearly LT Debt VS Equity VS FCFSYBX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M 150M

2.3 Liquidity

A Current Ratio of 2.71 indicates that SYBX has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.71, SYBX is doing worse than 69.88% of the companies in the same industry.
A Quick Ratio of 2.71 indicates that SYBX has no problem at all paying its short term obligations.
SYBX's Quick ratio of 2.71 is on the low side compared to the rest of the industry. SYBX is outperformed by 68.09% of its industry peers.
Industry RankSector Rank
Current Ratio 2.71
Quick Ratio 2.71
SYBX Yearly Current Assets VS Current LiabilitesSYBX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

6

3. Growth

3.1 Past

SYBX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 67.42%, which is quite impressive.
SYBX shows a strong growth in Revenue. In the last year, the Revenue has grown by 292.25%.
Measured over the past years, SYBX shows a small growth in Revenue. The Revenue has been growing by 5.99% on average per year.
EPS 1Y (TTM)67.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.61%
Revenue 1Y (TTM)292.25%
Revenue growth 3Y83.01%
Revenue growth 5Y5.99%
Sales Q2Q%-100%

3.2 Future

The Earnings Per Share is expected to grow by 21.62% on average over the next years. This is a very strong growth
Based on estimates for the next years, SYBX will show a very strong growth in Revenue. The Revenue will grow by 133.80% on average per year.
EPS Next Y74.59%
EPS Next 2Y39.85%
EPS Next 3Y25.54%
EPS Next 5Y21.62%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y133.8%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
SYBX Yearly Revenue VS EstimatesSYBX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 50M 100M 150M 200M
SYBX Yearly EPS VS EstimatesSYBX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 -100 -200 -300

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SYBX. In the last year negative earnings were reported.
Also next year SYBX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SYBX Price Earnings VS Forward Price EarningsSYBX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SYBX Per share dataSYBX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3 -4

4.3 Compensation for Growth

SYBX's earnings are expected to grow with 25.54% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.85%
EPS Next 3Y25.54%

More info and screens

0

5. Dividend

5.1 Amount

SYBX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SYNLOGIC INC

NASDAQ:SYBX (2/21/2025, 8:00:01 PM)

1.36

-0.05 (-3.55%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)03-17 2025-03-17/amc
Inst Owners64.61%
Inst Owner Change-96.55%
Ins Owners13.48%
Ins Owner Change-0.01%
Market Cap15.91M
Analysts43.33
Price Target1.02 (-25%)
Short Float %0.53%
Short Ratio1.18
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)112.66%
Min EPS beat(2)94.55%
Max EPS beat(2)130.76%
EPS beat(4)2
Avg EPS beat(4)-14.74%
Min EPS beat(4)-210.86%
Max EPS beat(4)130.76%
EPS beat(8)6
Avg EPS beat(8)-3.71%
EPS beat(12)9
Avg EPS beat(12)-0.02%
EPS beat(16)13
Avg EPS beat(16)1.81%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)33.33%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.71
P/FCF N/A
P/OCF N/A
P/B 1.21
P/tB 1.21
EV/EBITDA N/A
EPS(TTM)-4.16
EYN/A
EPS(NY)-0.48
Fwd EYN/A
FCF(TTM)-3.13
FCFYN/A
OCF(TTM)-3.13
OCFYN/A
SpS0.24
BVpS1.12
TBVpS1.12
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -331.21%
ROE -524.44%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-56.71%
ROA(5y)-47.7%
ROE(3y)-85.16%
ROE(5y)-67.93%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.13
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 5.1%
Cap/Sales 1.36%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.71
Quick Ratio 2.71
Altman-Z -33.26
F-Score4
WACC9.51%
ROIC/WACCN/A
Cap/Depr(3y)22.59%
Cap/Depr(5y)25.84%
Cap/Sales(3y)35.69%
Cap/Sales(5y)47.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)67.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.61%
EPS Next Y74.59%
EPS Next 2Y39.85%
EPS Next 3Y25.54%
EPS Next 5Y21.62%
Revenue 1Y (TTM)292.25%
Revenue growth 3Y83.01%
Revenue growth 5Y5.99%
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y133.8%
EBIT growth 1Y42.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y37.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y36.39%
OCF growth 3YN/A
OCF growth 5YN/A